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Abstract 
Rhabdomyosarcoma (RMS) is a rare malignant soft tissue neoplasm comprised of cells derived from the primitive 
mesen¬chyme. About 35% of RMS arises in the head and neck, are are classified as parameningeal and non-para-
meningeal forms. These are the most common soft tissue sarcoma of the children, adolescents and young adults. 
Their etiopathogenesis and its molecular relevance have been emphasized. The first line of treatment is radical 
excision and this is usually supplemented by radiotherapy. It is believed that adjunct combination chemotherapy 
may greatly improve the prognosis. Inadequately treated tumours grow in an infiltrative manner and recur in a high 
percentage of cases. Bone does not constitute an effective barrier to the growth of the tumour and bone invasion is 
a frequent finding in head and neck rhabdomyosarcomas.
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Introduction
Sarcomas are rare, malignant tumors that can arise from 
mesenchymal tissues at any body site. The histopatholo-
gic spectrum of sarcomas is broad, presumably because 
the embryonic mesenchymal cells from which they ori-
ginate have the capacity to mature into striated skeletal 
and smooth muscle, adipose and fibrous tissue, bone, 
and cartilage(1).
Rhabdomyosarcoma was initially described by Weber in 
1854 (2).  The first published example of rhabdomyosar-
coma, the malignancy of striated muscle, was probably 
a tongue lesion reported in 1854 (3). It is the most com-
mon soft tissue sarcoma of the children, adolescents and 
young adults. They are classified histologically into Em-
bryonal, Botryoid, Alveolar and Pleomorphic varieties, 
and tend to occur predominantly in three regions: the 
head and neck, genitourinary tract, and upper and lower 
extremities (4). 
Rhabdomyosarcoma may be defined as a malignant tu-
mor of the rhabdomyoblasts with a microscopic picture 
simulating that of striated muscle cells (5). Although an 
uncommon lesion, this tumor is among the most com-
mon head and neck cancers in young persons (3).
Rhabdomyosarcoma (RMS) is the most common soft-
tissue sarcoma in pediatric patients and accounts for 
nearly 20% of soft-tissue sarcomas overall. In children, 
close to 50% of rhabdomyosarcomas arise in the head 
and neck, most commonly in the parameningeal region, 
orbit, oral cavity, nasopharynx, sinuses, ear, and neck 
(3).
Etiopathogenesis
Skeletal muscle fiber regeneration is a phenomenon that 
recapitulates several steps of muscle embryogenesis. 
Originally located in close contact with the myofibre, 
inside the myofibril basement membrane coating (so-
called endomysium tube), satellite cells play a crucial 
role in this process since they function as myogenic stem 
cells (6).
Rhabdomyosarcoma is considered to result from ma-
lignant change of primitive mesenchymal cells rather 
than differentiated muscle (7). These primitive mesen-
chymal tissues exhibit a tendency toward myogenic di-
fferentiation and probably originate from satellite cells 
associated with the embryogenesis of skeletal muscle. 
Rhabdomyosarcomas (RMS) are thought to originate 
from immature cells that are destined to form striated 
skeletal muscle; however, these tumors can arise in lo-
cations where skeletal muscle is not typically found (eg, 
the urinary bladder). Undifferentiated sarcomas (UDS) 
derive from mesenchyme that cannot be ascribed to a 
specific tissue lineage (1).
No clear etiologic factors have been identified to ac-
count for the occurrence of these malignant neo-
plastic growths.There is, however, increasing evi-
dence that gene abnormalities may play a role in the 
development of some childhood malignancies, especia-
lly rhabdomyosarcoma(8). Cytogenetic and molecular 
studies have identified chromosomal translocations and 
mutations in oncogenes (2).
Commitment and maintenance of skeletal muscle diffe-
rentiation during normal skeletal muscle myogenesis, as 
well as in Rhabdomyosarcoma, is regulated by a family 
of closely related genes (eg. myoD1, myogenin, myf-5, 
MRF-4), termed the MyoD family. These genes encode 
a series of DNA-binding proteins that control the acti-
vation and transcription of genes encoding muscle en-
zymes and proteins, such as creatine kinase and desmin. 
Of these genes, myoD1 and myf-5 most likely contribu-
te to the determination of the myogenic state; whereas 
myogenin includes terminal differentiation and MRF-4 
is thought to be involved in the maintenance of the ma-
ture adult muscle phenotype. MyoD1 and myogenin are 
considered useful markers in diagnosing Rhabdomyo-
sarcomas and for differentiating it from other soft tissue 
tumors (9).   
Molecular Pathology
Molecular pathology to classification of RMS may help 
to solve the controversies in RMS subtypes by the use 
of objective criteria based on genetic differences. It has 
been described that patients with the variant PAX7-
FKHR translocation have a more favorable prognosis 
and there has been a strikingly better outcome in pa-
tients with metastatic disease and variant-trans location-
positive alveolar RMS (estimated 4-year overall survi-
val, 75% vs. 8% for patients with PAX3-FKHR-positive 
alveolar RMS) (10).
Myogenin is considered a sensitive and specific marker 
for RMS and this is thought to be more specific than 
desmin and muscle-specific actin and more sensitive 
than myoglobin (11). Myogenin and desmin are sensiti-
ve and specific immunohistochemical markers for head 
and neck RMS. Other immunohistochemical markers 
have been used to help with the difficult diagnosis of 
RMS, including myogenic nuclear regulatory proteins 
such as MyoD1 and myogenin that act as transcription 
factors and stimulate myogenesis. MyoD1 is a marker of 
the myoid lineage which is expressed by fetal myoblasts 
and is important for the transition from cell proliferation 
to differentiation. A variety of differentiated cell types 
can be converted into skeletal muscle after transfection 
with MyoD1 through the activation of muscle-specific 
genes. Myogenin is a myoid differentiation marker. In 
this respect, it has been reported that the loss of normal 
proliferation and differentiation control may theoretica-
lly lead to the formation of RMS (2).
Genetic abnormalities have been demonstrated in rhab-
domyosarcomas and implicated in the pathogenesis of 
rhabdomyosarcoma. One line of genetic study is on the 
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tumor suppressor gene, p53. Rhabdomyosarcoma is the 
basic cancer type of a familial cancer syndrome, the Li-
Fraumeni syndrome (12). In Li-Fraumeni syndrome fa-
milies, there is a germline p53 mutation (13). It is specu-
lated that Li-Fraumeni p53 mutant alleles may be weak 
alleles that lack dominant negative activity and can be 
tolerated and passed in the germline of families. In non-
familial, sporadic cases of rhabdomyosarcoma, there is 
a high frequency and diversity of p53 mutation(14). P53 
gene is located on the short arm of chromosome 17 (17p). 
The wild type p53 controls cell proliferation at a G1/S 
checkpoint in the cell cycle and the mutated type presu-
mably loses this regulatory function so that the affected 
tissue undergoes tumorous growth (14). Second line of 
genetic study on rhabdomyosarcoma concerns the loss 
of heterozygosity of the short arm of chromosome 11 
(llp), which occurs in embryonal rhabdomyosarcomas. It 
is presumed that a recessive tumor suppressor gene, the 
Rb gene, resides in the region 11 p 15.5-terminal. Loss 
of heterozygosity with inactivation of the paternal Rb 
gene, that is, by DNA methylation or other events, would 
lead to tumorous growth. The third line of study regards 
translocation between the long arms of chromosomes 2 
and 13, designated as t(2;13) (q35;q14) (12).  This type 
of cytogenetic abnormality is mainly found in alveolar 
rhabdomyosarcoma. The translocation results in fusion 
of a transcription regulator gene, the PAX3, with a trans-
cription factor gene, the ALV, near the translocation site 
of chromosome 2. This fusion in turn presumably results 
in transcriptional deregulation and tumorigenesis. Besi-
des these three lines of study, activation and mutation of 
oncogenes, particularly the RAS oncogenes, have been 
demonstrated in rhabdomyosarcomas (8).
Antibodies against muscle-specific intermediate filament 
desmin, muscle-specific actin, and myoglobin provide 
additional information in the diagnosis of Rhabdomyo-
sarcomas but may lack sensitivity and specificity. Ex-
tensive myogenesis studies have revealed the existence 
of a family of genes encoding a series of DNA-binding 
proteins that play a critical role in the commitment of 
mesenchymal progenitor cells to the myogenic lineage 
and in their subsequent differentiation (9).
Alveolar rhabdomyosarcoma has been demonstrated to 
have a characteristic translocation ((2;13)(q35;q14)) fu-
sing the PAX3 gene with the FKHR gene. The PAX3 
gene is believed to regulate transcription during early 
neuromuscular development and FKHR is a member of 
the forkhead family of transcription factors. It is hypo-
thesized that the fusion transcription factor inappropria-
tely activates transcription of genes that contribute to a 
transformed phenotype. Genomic amplification of such 
genes as MYCN, MDM2, CDK4 and PAX7-FKHR is 
mainly a feature of the alveolar subtype. Loss of alle-
les and imprinting at 11p15.5 together with disruption 
of genes such as IGF2 have also been implicated in 
rhabdomyosarcoma development. Activation of IGF2 
seems to be a feature of all rhabdomyosarcomas, even 
though 11p15.5 loss of heterozygosity and IGF2 loss of 
imprinting are alterations predominantly associated with 
the embryonal and alveolar subtypes, respectively. The 
ALK gene is located at 2p23 and encodes a novel trans-
membrane receptor tyrosine kinase, ALK, belonging to 
the insulin receptor family of tyrosine kinase. This pro-
tein is expressed in normal tissue during embryogenesis 
but is absent from all types of adult tissue, except for 
scant weakly positive cells in the central nervous sys-
tem, in scattered neurones, glial cells and endothelial 
cells. NPM-ALK chimeric protein is thought to be up-
regulated as a result of the t(2;5) as classically seen in 
anaplastic large cell lymphoma, resulting in an up-regu-
lated mitogenic signal through aberrant phosphorylation 
of intracellular substrates (15).
Embryonal RMS is associated with loss of heterozygo-
sity (LOH) at the 11p15 locus, which affects the expres-
sion of insulinlike growth factor (IGF), a growth factor 
of RMS. p16INK4A (p16) gene induces dephosphoryla-
tion of pRB by inhibiting binding of cyclin-dependent 
kinase (CDK)4 and CDK6 to cyclin D, resulting in G1 
growth arrest. The discovery that p16 gene is mutated or 
deleted in a striking proportion of human tumors raised 
the possibility that abnormalities in p16 might predispo-
se to cancer development (16).
In contrast to alveolar neoplasms, embryonal RMS ra-
rely bear this genetic lesion. In embryonal tumors where 
the above noted translocations are not seen, LOH at the 
11p15 locus is almost uniformly identified. This region 
of the short arm of chromosome 11 contains a number 
of imprinted genes implicated in oncogenesis, including 
H19, IGF2 and p57KIP2; however, the relevant genetic 
target of this putative loss-of-function mutation has yet 
to be identified. The 11p15 region is imprinted in normal 
tissue, with only the paternal allele being transcribed 
(15).
Myostatin, a member of the TGF-b superfamily, is a key 
regulator of skeletal muscle growth and development. 
Myostatin has been shown to inhibit the proliferation of 
normal myoblasts by altering the levels and activity of 
members of the cell cycle machinery. Specifically, in res-
ponse to myostatin treatment, the cyclin-dependent ki-
nase inhibitor p21 is upregulated and the level of Cdk2 
is slightly reduced resulting in a loss of cyclin-E–Cdk2 
activity. This loss of activity results in the loss of Rb 
phosphorylation causing cell cycle arrest (14).
S Charrasse et al have analysed cadherin-mediated cell 
adhesion in RMS, nonepithelial tumors of skeletal mus-
cle origin, and found multiple defects in the expression 
of cadherins and catenins in RMS-derived cell lines. Di-
fferent mechanisms might be involved in this decrease 
in cadherin and catenin expression. In particular, the al-
tered expression and/or activity of transcription factors, 
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which regulate the promoters of the adherens junction 
proteins, might cause these expression defects. Slug and 
Snail, two zinc-finger transcription factors, decrease E-
cadherin promoter activity in cancers. Additionally, CpG 
hypermethylation of the E-cadherin promoter is an im-
portant mechanism of E-cadherin gene inactivation(17).
AKT plays a critical role in controlling the balance bet-
ween cell survival and apoptosis. RMS cell lines that 
express high level of phospho-AKT, at least RH30 and 
SMS-CTR, seem to depend on AKT pathway for cell 
proliferation and survival (18,19).
Clinical appearance
The incidence of RMS is highest in children 1-4 years of 
age, falling to a lower rate at 10-14 years, and remaining 
steady between 15-19 years of age (10). It is rare after 45 
years of age (3). A slight preference for males has been 
reported, with these tumors mainly occurring in the first 
and second decades of life (2). 
The presenting signs and symptoms of RMS are varia-
ble, and are influenced by the site of origin, the age of 
the patient, and the presence or absence of distant me-
tastases (1). The signs and symptoms may include pain, 
paresthesia, loss of teeth and trismus as a result of fac-
tors such as advanced tumor stage, infiltrative growth 
and tumor location (2). A history of antecedent trauma is 
uncommon, and fever is only rarely present (1). 
The head and neck are the most frequently affected re-
gions, followed by the orbit (35% of cases), trunk and 
extremities, intra-abdominal organs and genitourinary 
tract (23%) (2). Site predilection in the oral cavity va-
ries according to diffe rent authors, some finding that the 
palate is the commonest site, while others report that the 
tongue is the most common site (10). There is general 
agreement that the orbit is the most commonly affected 
site. The nasopharynx and middle ear regions follow in 
frequency although at least one major study suggests that 
the soft tissue of the neck may be the second most com-
mon site (7). The parameningeal sites, which include na-
sopharynx, nasal cavity, paranasal sinuses, pterygopala-
tine, and infratemporal fossa and middle ear, have been 
associated with extension directly to the central nervous 
system (CNS) in 35% of cases within 1 year of diagnosis 
(7). (Table 1)
The clinical appearance may exhibit smooth or lobula-
ted surface, sometimes botryoid or grape cluster–like in 
Site Age /Sex
Right angle, mandible
Right mandible, retromolar area
Left cheek
Right posterior mandible
Right mandible, alveolus
Left cheek and maxilla
Left maxillary sinus and alveolus
Right buccal fold, cheek and infraorbital area7
20/M
12/M
7/M
16/M
22/F
19/M
15/M
46/F
Left palate
Left palate
Left maxillary gingival
Right cheek 8
22/M
10/F
16/M
7/F
Fetal tongue19 Antenatal finding
Alveolus20 11/F
Intraosseous (mandible)21 6/M
Alveolus of mandible22 10/F
Erythematous nodule located on the distal portion of the tongue23 10/F
Right cervical region5 67/M
Left buccal mucosa
left, posterior maxillary ridge10
18/F
19/M
Right side of dorsum of tongue24 2 1/2/M
Uvula25 15/M
gingival mass involving the anterior maxillary gingiva11 33/F
Temporal bone26 4/M
Intraosseous (ramus and body of mandible)2 4/M
Floor of mouth4 11/M
Table 1. A few reported cases of Rhabdomyosarcoma at diverse locations. 
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appearance and definitely becomes fixed to surrounding 
tissues at an early stage (3).
30% of all head and neck RMS have their origin in in-
traoral and pharyngeal structures. In affected patients, 
the tumor expands and infiltrates the muscle from which 
it arises, presenting first as a well demarcated nodule 
or polypoid lesion with a soft or gummy consistency. 
When these lesions grow rapidly they may cause dysp-
nea, dysphagia, and cough, including acute respiratory 
obstruction (23).
Initial symptoms may be vague, and may mimic other 
childhood and adolescent, soft-tissue sarcomas such as 
fibrosarcoma, leiomyosarcoma and neu rofibrosarcoma 
(10). Of the sarcomas involving the oral cavity in chil-
dren, rhabdomyosarcoma, alveolar soft-part sarcoma, 
fibrosarcoma, leiomyosarcoma, and Kaposi sarcoma are 
the most common (20).
However, neuroblastoma, another small cell tumor cha-
racterized by a diffuse pattern of small round cells and 
the presence of rosettes/pseudorosettes with pale eosi-
nophilic material is quite similar to the alveolar variant 
of rhabdomyosarcoma. The frequently elevated level of 
urinary catecholamines in neuroblastoma aids in the di-
fferential diagnosis (20-22).
The differential diagnosis also includes vascular malfor-
mations, within which the most common affecting the 
pediatric airway is the lymphatic or lymphatic-venous 
malformation (LM). Lymphatic malformations are ty-
pically described as cystic lesions present at birth that 
grow in proportion to the child. Although most head and 
neck LM are present at birth, they may not become clini-
cally apparent until a child develops an upper respiratory 
infection or sustains trauma to the area (23).
Diagnosis
It is possible to detect intraoral mass (RMS tongue) by 
antenatal ultrasound scan and it warrants a careful pe-
rinatal multidisciplinary team approach.
 
The treatment 
of RMS is site-specific and multidisciplinary efforts 
offer best results.
  
An initial complete primary resection 
of tumor with negative gross and microscopic margins 
is ideal, if possible. Another option is initial incisional 
biopsy followed by neoadjuvant therapy, to preserve the 
organ and secondary excision if required. As the sole ra-
diation modality, fractionated high-dose-rate (F–HDR) 
brachytherapy achieved excellent local control and di-
sease free survival, in properly selected children with 
soft tissue sarcomas, while preserving normal bones and 
organ development (24).
Hemophagocytosis is the latest diagnostic clue to mono-
cytic-histiocytic proliferative disorders and are also fre-
quently observed in other hematologic malignancies. Its 
occurrence in solid tumors is rare, but has been reported 
in small-cell lung carcinoma, breast carcinoma, medu-
lloblastoma, hemangioendotheliosarcoma and recently, 
rhabdomyosarcoma (12).
Computed tomography and magnetic resonance imaging 
(MRI) with contrast are helpful in generating a diffe-
rential diagnosis for the child with cystic lesions of the 
head and neck. These give complementary information 
regarding the bony and soft tissue extension of the lesion 
(23).
Types
There are predominantly three types of Rhabdomyosar-
comas:
1. Embryonal variant: Accounts for approximately 49% 
of all rhabdomyosarcomas and affects mostly children 
younger than 10 years of age, but it also occurs in ado-
lescents and young adults. It is rare in patients older 
than 40 years of age.
2. Alveolar variant: It accounts for almost 30% of all 
rhabdomyosarcomas and tends to arise in patients of 
age group 10-25 years. It has predilection for deep soft 
tissues of the extremities. The tumor may arise at other 
places also though they are rare.
3. Pleomorphic variant: This is a rare variant which al-
most arises in adults older than 45 years. They arise 
mostly in the deep soft tissues of the extremities (4).
Enzinger and Weiss proposed two histogenetic possi-
bilities for rhabdomyosarcoma: (a) primitive and un-
differentiated mesenchyme origin and (b) embryonal 
muscular tissue origin (24-26).
The histopathological and molecular spectrum manifes-
ted by RMS has led to many classification systems. Horn 
and Enterline(mid 1900s) divided rhabdom yosarcomas 
into embryonal (ERMS), alveolar, botryoid, and 
pleomorphic subtypes. In 1994, histological and biolo-
gical studies have resulted in the International Classifi-
cation of RMS and hence four broad subtypes of RMS 
were established: (a) botr yoid and spindle cell RMS 
(both less common variants of ERMS); (b) embryonal 
RMS, generally having a superior prognosis; (c) alveo-
lar (including the solid-alveolar variant) RMS, generally 
having a poorer prognosis and (d) undiffe rentiated sar-
coma, also generally having a poorer prognosis. Finally, 
a category of sarcoma nor otherwise specified was crea-
ted for tumors that could not be classified into a speci-
fic subtype. Recently it was added to this classification 
a subtype of RMS with rhabdoid-like features, whose 
prog nosis is not presently valuable. It is now apparent 
that rhabdomyosarcoma comprises a group of morpho-
logically similar but biologically diverse lesions (10).
Histopathologic spectrum
Majority of oral rhabdomyosarcomas are of embryonal 
type, with small, round or oval tumor cells resembling 
embryonal or developing voluntary muscle cells. These 
cells have a finely granular eosinophilic cytoplasm with 
few cells demonstrating fasciculation or cross-striations. 
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There often is a fibrillar material imparting a clear zone 
around the nucleus, and the nucleus itself is typically 
enlarged. On the other hand, more well-differentiated 
tumors demonstrate elongated, strap shaped or tadpole-
shaped rhabdomyoblasts. Occasional giant cells with 
enlarged or multiple nuclei can also be seen. Mitotic 
figures are often seen and may be abnormal. The back-
ground stroma is scanty and consists of moderately loose 
to dense fibrous tissue. A background of poorly differen-
tiated ovoid mesenchymal cells is frequently noted, and 
myxoid zones are commonly seen in the stroma (3).
Histologically, rhabdomyosarcomas were classified by 
Horn and Enterline into four subtypes: pleomorphic, 
alveolar, embryonal, and botryoid. However, botryoid 
rhabdomyosarcoma is a descriptive term for a rhabdom-
yosarcoma with polypoid or grape-like gross appearance 
and is considered a variant of the embryonal form. The 
more differentiated cells are spindle-shaped or strap sha-
ped. Longitudinal and occasionally cross striations can 
be identified. Binucleation is common, and nuclei are 
frequently vesicular (8).
The definitive diagnosis is based on histological evi-
dence of myogenesis in the tumor, including giant or 
multinucleated myoblasts, strap or tadpole cells, and 
individual tumor cells with or without cross-striations 
and densely eosinophillic cytoplasm. However, as rhab-
domyosarcomas tend to display a spectrum of wide his-
tological features and is often poorly differentiated, its 
diagnosis is often difficult (9). 
Alveolar RMS is typically comprised of small round 
densely packed cells, arranged around spaces resem-
bling pulmonary alveoli. A solid variant form of alveolar 
RMS has been identified, which consists of small round 
densely packed cells without the characteristic alveolar 
spaces. There does not appear to be any prognostic sig-
nificance of the solid alveolar variant. Alveolar tumors 
harbor a distinguishing chromosomal translocation mar-
ker, typically t(2;13)(q35;q14). Pleomorphic RMS is 
currently rarely diagnosed and is characterized by large 
aggregates of anaplastic cells (15).
Histological classification has prognostic significance. 
For instance, the botryoid and spindle cell variants have 
a favourable prognosis, while embryonal rhabdomyo-
sarcomas tend to have a better prognosis than alveolar 
rhabdomyosarcoma. It is therefore important to classify 
these tumours correctly (12).
Treatment
In the advanced stages of the disease, because of the in-
filtrative growth, and depending on the site of the tumor, 
pain, paresthesia, loosening of the teeth, and trismus oc-
cur (10).
Treatment therefore is by a multidisciplinary approach. 
It consists of surgical removal of the tumor followed by 
multiagent chemotherapy with or without radiotherapy 
since RMS tend to metastasize to bone marrow, bone 
marrow aspiration should be a part of the staging proce-
dure (4,5,11). Total tumor resection confers the most fa-
vorable treatment outcome. However, due to its invasive 
nature complete tumor resection is often difficult (5). 
Prognosis remains poor for patients with metastatic di-
sease at presentation and poor response to chemotherapy. 
Radiotherapy is targeted at the pre-chemotherapy sites 
of disease. Chemoradiation following complete surgical 
resection appears to be the ideal therapy (5). Multimodal 
approaches combining surgical resection, radiation, and 
systemic chemotherapy need further investigation(1,5).
Metastasis may develop during the course of illness in 
approximately 20% of the cases with major sites be-
ing the lung, lymph node and bone marrow followed 
by heart, brain, meninges, pancreas, liver and kidney. 
Lungs are involved in nearly two thirds of patients of 
metastasis (4,5).
Oral rhabdomyosarcoma favourably is treated by radical 
surgical excision followed by multiagent chemotherapy, 
usually a combination of vincristine, dactinomycin, and 
cyclophosphamide. If complete resection is not possible 
then postoperative radiotherapy may be  employed. Fi-
ve-year survival rates have improved dramatically from 
less than 10% before the 1960s to 65% today. Stage I 
lesions have an even better prognosis (80%). Metastasis, 
when it occurs, is via either blood or lymphatic vessels, 
usually to cervical lymph nodes, lungs, bones, or brain 
(3).
ERMSs are treated with multimodality therapy and have 
a favorable prognosis relative to other subtypes of RMS, 
with classic ERMS having a 66% 5-year survival rate 
and botryoid and well-differentiated spindled variants 
having a nearly 90% 5-year survival rate. Adverse prog-
nostic factors in ERMS include adult age, paramenin-
geal location, head and neck location, large size, and 
unresectability (3).
Complete resection with histologically free margins is 
often unfeasible without exenteration, but chemotherapy 
and radiotherapy enable complete remission in the majo-
rity of cases, so mutilating surgery is currently reserved 
only for unresponsive tumours. Unfortunately, important 
radiotherapy-induced late sequelae (functional changes, 
ie., cataract, orbital hypoplasia, facial asymmetry) are 
common (18).
Prognostic relevance
Oral rhabdomyosarcomas are classified within the non-
parameningeal group of tumors, which do not tend to 
invade the central nervous system (10).  As a result of 
their aggressive neoplastic behavior characterized by 
immature and highly invasive cells, RMS are associated 
with high rates of recurrence and generalized metasta-
ses through the hematogenic and/or lymphatic routes(2). 
With the advent of combined surgical, chemo therapeutic, 
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and radiotherapeutic management of RMS, the five-year 
survival rate is approximately 85% for this RMS subty-
pe (10). 
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